Seres Therapeutics (NASDAQ:MCRB – Get Rating) and Acer Therapeutics (NASDAQ:ACER – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation. Volatility & Risk Seres Therapeutics has a beta of […]
Seres Therapeutics (NASDAQ:MCRB – Get Rating) had its target price trimmed by Chardan Capital from $12.00 to $10.00 in a report released on Friday, The Fly reports. Several other brokerages have also issued reports on MCRB. JPMorgan Chase & Co. began coverage on shares of Seres Therapeutics in a report on Friday, April 21st. They […]
Seres Therapeutics (NASDAQ:MCRB – Get Rating) had its price objective reduced by Chardan Capital from $12.00 to $10.00 in a research note released on Friday morning, The Fly reports. A number of other brokerages also recently commented on MCRB. Canaccord Genuity Group lifted their price target on shares of Seres Therapeutics from $11.00 to $15.00 […]
Seres Therapeutics (NASDAQ:MCRB – Get Rating) had its target price cut by research analysts at Chardan Capital from $12.00 to $10.00 in a note issued to investors on Friday, The Fly reports. Chardan Capital’s target price indicates a potential upside of 87.97% from the company’s previous close. MCRB has been the subject of several other […]
Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) saw strong trading volume on Wednesday . 922,325 shares changed hands during trading, a decline of 32% from the previous session’s volume of 1,365,200 shares.The stock last traded at $6.41 and had previously closed at $6.16. Analysts Set New Price Targets A number of brokerages have commented on […]